Image Source: Pexels

The healthcare sector, particularly managed‑care insurers, has been under pressure recently, driven by rising medical costs, regulatory scrutiny, earnings disappointments, and reputational challenges. Many of these companies’ stocks have significantly lagged the broader market, and investors are grappling with whether these sectors present contrarian value opportunities or structural pitfalls.

A high‑profile case is UnitedHealth: after a December 2024 incident—the murder of its insurance‑division CEO Brian Thompson—plus unexpected medical cost overruns and a DOJ investigation, the company endured a painful sell‑off. Its stock plunged by around half year‑to‑date earlier in 2025.

Yet, in a classic “buy the dip” moment, Warren Buffett’s Berkshire Hathaway added over 5 million UNH shares (worth approximately $1.6 billion) by end of June. This triggered a “Buffett Bounce,” with UNH shares rising substantially upon the announcement, Analysts now see UNH as undervalued, with forward P/E at or below historical norms, a decent dividend yield (~3%), and a consensus Buy rating with upside potential above 20%.

This recovery has pulled other managed‑care stocks—including Elevance Health (ELV)—into renewed investor focus, with many seeing longer‑term upside as the sector’s economic fundamentals reassert themselves.

Stock Profiles

UNITEDHEALTH (UNH)

Once a Wall‑Street favorite for consistent profits and dominant scale, UNH now contends with broad operational headwinds. It slashed its 2025 earnings guidance to around $16 per share (vs. ~$20.64 expectation and prior guidance of $30+), due to soaring costs, Medicare reimbursement challenges, and regulatory and legal complications. The company faces intensive scrutiny, including criminal probes related to Medicare billing and claims practices.

However, for value investors, the valuation reset is significant. With Buffett’s entry and positive analyst sentiment, some see UNH as a turnaround play—not without risks, but potentially rewarding for those betting on operational reforms under returning CEO Stephen Hemsley and cost containment initiatives.

The stock, with a market cap of $275 billion, trades at 13 times trailing earnings and 17 times forward earnings. It carries a favorable Price to Sales Ratio of 0.65, and provides a yield of 2.8%.

CIGNA (CI)

Two months ago, Cigna was trading near $297, with relatively muted volatility compared to peers. Cigna aligns with the broader managed‑care sector and likely shares similar cost and regulatory pressures. Its profile suggests steadiness and defensive appeal, though without the explosive risk/reward of UNH at current levels.

This $79 billion market cap stock has a trailing price to earnings ratio of 16 and a forward P/E of 9. The price to sales ratio is an excellent 0.30. The stock sports a yield of about 2.5%.

CVS HEALTH (CVS)

CVS encompasses pharmacy chains, PBM services, and Aetna’s insurance plans. Although CVS’s integrated model offers resilience, its exposure to Medicare Advantage and cost pressures mirrors peers. Reports indicate investor focus on whether CVS can sustain momentum under its current management amid sector‑wide headwinds.

The stock has a market cap of $96 billion, a trailing P/E of 19, and a forward P/E of 9.6.The price sales ratio is a superior 0.23, with a fairly high yield of 3.9%.

ELEVANCE HEALTH (ELV)

Elevance Health was formerly Anthem. Analysts hold a bullish consensus “Buy” rating, with a 12‑month price target near $412—implying about 33% upside.

Elevance’s valuation appears attractive, with forward P/E near 10, following a 13 trailing P/E, and dividend yield around 2.2%. Though it has trended down from a 52‑week high over $567, the volatility is modest and relative fundamentals solid. Market forecasts place it as a stable performer in managed‑care. The market cap is $69.7 billion.

Conclusion

The current landscape offers a mix of risks and opportunities across healthcare plan stocks, the following which all have dividend yields above 2%:

• UnitedHealth (UNH) represents high-risk, high-reward territory. The battered valuation, combined with Buffett’s backing and potential for operational recovery, may appeal to contrarian, value-minded investors—but only for those comfortable with regulatory and reputational risks.
• Elevance Health (ELV) strikes a compelling balance between stability, valuation, and growth potential. With solid fundamentals and moderate upside, it’s positioned for cautious optimism.
• Cigna (CI) and CVS Health (CVS) are less volatile and potentially more defensively oriented—though sector-wide headwinds remain a concern.

For investors evaluating this sector, the decision likely hinges on risk tolerance and time horizon: are you looking for a possible rebound champion (UNH), a strong core holding (ELV), or stable, less dramatic exposure (CI) and (CVS)? Investors attracted to contrarian, value-oriented plays may find the sector appealing right now. However, the path forward depends on successful cost management, legal clarity, and renewed growth momentum.

Disclosure: Author didn’t own any of the above at the time the article was written. No investments are expressed or implied.

More By This Author: